C-Suite Speaks
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?
Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.
Neutrophil Extracellular Traps are a double-edged sword in the immune system, capable of both defending against pathogens and driving inflammatory diseases. Their complex role in health and disease is being approached by innovative researchers and biotechs, who are working to harness their power while mitigating their harmful effects.
Steven Damon, Micron Biomedical CEO, discusses the promising future of Micron’s microneedle technology, which allows for painless vaccine delivery through pressing a small patch onto the skin.
This is the second of a two-part profile of Hans Clevers, head of Pharma Research and Early Development at Roche, in which he talks about his vision for the future of personalized medicine.
CMO Tahamtan Ahmadi explained Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.
Beyond the cost savings of biosimilars, the true evolution in wet AMD treatment is happening by companies developing next-generation therapies that aim to reduce injection burden, introduce novel mechanisms, and potentially alter disease progression.
This is Part 1 of a 2-part profile of Hans Clevers, Head of Pharma Research and Early Development at Roche.
Artiva Biotherapeutics is hoping its NK cell therapy approach, which uses un-engineered cells, will prove effective in both oncologic and autoimmune indications and safe enough to be given in the community setting.
In Vivo caught up with Najat Khan, chief R&D and commercial officer at Recursion since mid-2024, about her new roles, the special combination with Exscientia and the company's clinical pipeline.
Takeda’s head of gastroenterology talked to In Vivo about the major’s plans for finding biomarkers for Crohn’s disease as part of a Euro-wide prevention and interception trial.
Having spun out its oncology business and put all of its eggs into a neuroscience-shaped basket, how is Alkermes executing on its 2024 stated strategy to return to its CNS roots?
Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions, as well as the potential of its Phase II asset bexmarilimab.
CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.
CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.
One month after announcing a pipeline pivot, Ovid Therapeutics talked to In Vivo about the importance of making strategic decisions with discipline, and the imminent neurology revolution.
Overseeing the diverse EMEA region as the regional president of Johnson & Johnson’s Vision business has been a whirlwind of activity for Jacqueline Henderson, in her role since 2023. Fresh back from the ESCRS 2024 meeting, she spoke to In Vivo about how J&J responds to market needs.
Attrition among biotechs and VCs holding onto their reserve capital for existing investments may have reduced the capital available for new life sciences funding, but UK-based LifeArc Ventures believes its recent activity is indicative of a general upswing.